title: [Immune dysfunction and cognitive deficit in stress and physiological aging. Part II: New approaches to cognitive disorder prevention and treatment ].
abstract: Long-term stress as well as physiological aging result in similar immunological and hormonal disturbances including hypothalamic-pituitary-adrenal) axis depletion, aberrant immune response (regulatory T-cells, Tregs, and T(h17)-lymphocyte accumulation) and decreased dehydroepian-drosterone synthesis both in the brain and in the adrenal glands. Since the main mechanisms of inflammation control, "prompt" (stress hormones) and "delayed" (Tregs), are broken, serum cytokine levels increase and become sufficient for blood-brain-barrier disruption. As a result peripheral cytokines penetrate into the brain where they begin to perform new functions. Structural and functional alterations of blood-brain-barrier as well as stress- (or age-) induced neuroinflammation promote influx of bone marrow derived dendritic cells and lymphocyte effectors into the brain parenchyma. Thereafter, mass intrusion ofpro-inflammatory mediators and immune cells having a lot of specific targets alters the brain work that we can observe both in humans and in animal experiments. The concept of stressful cognitive dysfunction, which is under consideration in this review, allows picking out several therapeutic targets: 1) reduction of excessive Treg accumulation; 2) supporting hypothalamic-pituitary-adrenal axis and inflammatory reaction attenuation; 3) recovery of dehydroepiandrosterone level; 4) improvement of blood-brain-barrier function.
authors.forename: A L
authors.initials: AL
authors.lastname: Pukhal'skiĭ
authors.forename: G V
authors.initials: GV
authors.lastname: Shmarina
authors.forename: V A
authors.initials: VA
authors.lastname: Aleshkin
mesh_terms: D000222:Adaptation, Physiological; D000223:Adaptation, Psychological / Q000502:physiology; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000375:Aging / Q000187:drug effects / Q000502:physiology; D057912:Angiotensin II Type 2 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000473:pathology / Q000502:physiology; D003072:Cognition Disorders / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D016207:Cytokines / Q000378:metabolism; D003687:Dehydroepiandrosterone / Q000494:pharmacology; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism; D007154:Immune System Diseases / Q000209:etiology / Q000378:metabolism; D018942:Macrolides / Q000494:pharmacology; D010913:Pituitary-Adrenal System / Q000378:metabolism; D013312:Stress, Physiological / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000473:pathology / Q000502:physiology
chemical_list: D000276:Adjuvants, Immunologic; D057912:Angiotensin II Type 2 Receptor Blockers; D016207:Cytokines; D018942:Macrolides; D003687:Dehydroepiandrosterone